leader orthoped midst turnaround
challeng remain fore initi neutral
zimmer biomet diversifi medic technolog compani
design manufactur commerci broad rang
musculoskelet product leadership posit varieti area
current midst turnaround new management helm
qualiti remedi effort one zbh manufactur facil
progress revenu guidanc equat xfx
view achiev remedi effort manufactur facil
may take longer anticip interact fda continu
requir intens focu qualiti improv delay product
gain depress gross margin hamper sale momentum due
dynam multipl challeng could impact time
management expect two-year turnaround initi neutral
guidanc appear achiev valuat attract
result xfx growth xfx turnaround
stori appear take shape pipelin new product
yet releas robot system joint reconstruct
limit launch help improv overal revenu
growth guidanc appropri conserv valuat
ntm price-to-earnings attract
management unabl provid timelin qualiti remedi
suppli improv recent call view
management commentari assuag concern around on-go issu
hamper upsid growth leav us unsur
issu ultim rear-view mirror management
see issu prevent achiev
guidanc resourc continu divert support
ultim expect share remain rang bound
turnaround play make progress right ship
gener sizabl would becom construct
near-term risk abat growth level pick higher rate
valuat zimmer biomet rate neutral risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
compani descript zimmer biomet diversifi medic technolog
compani design manufactur broad rang musculoskelet
product zimmer hold found justin zimmer took
current form zimmer acquir biomet inc april today zimmer
biomet oper global countri employe across
zimmer biomet long-term goal includ return subsequ grow
market growth rate time investor expect modest
oper margin improv return ep growth beyond
invest thesi current midst turnaround new
management helm qualiti remedi effort one zbh
manufactur facil progress revenu guidanc equat
xfx view achiev remedi effort
manufactur facil may take longer anticip interact
fda continu requir intens focu qualiti improv
delay product gain depress gross margin hamper
sale momentum due dynam multipl challeng
could impact time management expect two-year turnaround
guidanc report revenue growth fx adj ep
modest om expans expect model om expans
primarili qualiti remedi effort subsid suppli
stock restor time expect higher gm pressur limit
invest thesi view zimmer biomet
zimmer biomet diversifi medic technolog compani design manufactur commerci broad rang musculoskelet
product leadership posit varieti area current midst turnaround new management helm qualiti remedi
effort one zbh manufactur facil progress revenu guidanc equat xfx view achiev
remedi effort manufactur facil may take longer anticip interact fda continu requir intens focu
qualiti improv delay product gain depress gross margin hamper sale momentum due dynam multipl
challeng could impact time management expect two-year turnaround initi neutral
expand thesi posit view zimmer biomet comprehens product portfolio aggreg competit share leader
musculoskelet market zimmer biomet abl capit sustain demograph epidemiolog driver musculoskelet condit
result growth in-lin broader musculoskelet market ie lsd long run near-term challeng subsid valuat well
appear attract discount comp group ntm price-to-earnings vs ntm price-to-earnings believ current valuat reflect investor fatigu
turnaround stori drag sinc begin take anoth quarter expect zimmer biomet potenti
eclips market growth rate put complet turnaround
product perspect believ zimmer biomet stand-out product leader respect area zimmer biomet
robot offer enter grow larg joint reconstruct robot market rosa rosa system expect beta-launch
full launch expect addit believ rosa applic brain spine combin total knee applic may appeal
custom base broad applic even applic though zimmer biomet enter robot market joint reconstruct behind
entrench competitor buy smith nephew snn rate may challeng make lost time
smith nephew forg ahead addit investor still know certain aspect rosa regard total knee applic cut
mechan action unknown make difficult gaug key appeal joint reconstruct custom compar exist
product offer market investor expect learn next month
turn management comment zimmer biomet experi sustain gm pressur remedi effort suppli chain take
away product gain would otherwis off-set stabl on-going price pressur lsd addit zimmer biomet continu
spend addit dollar qualiti remedi prevent potenti higher revenu ep growth invest next
quarter resourc divert address on-go qualiti issu due dynam model forward revenu compound-annual-growth-rate
year forward ep compound-annual-growth-rate lowest amongst larg cap medic technolog compani gener signific free cash flow expect
near-term capit alloc remain focus reduc debt level time follow de-lever expect consid share
repurchas share repurchas author help boost top bottom line growth
make us bullish zimmer biomet believ management resolv much fundament qualiti challeng improv corpor
cultur integr legaci zimmer legaci biomet divis posit quarterli result may follow would look indic improv
varieti metric includ employe rate review fda regulatori commun channel check physician believ new
management name ceo bryan hanson join compani recent help improv zimmer biomet employe moral corpor cultur
organiz cultur turnaround take time happen slow pace regardless leadership immedi impact
comprehens product portfolio abl compet current healthcar environ
would remis didnt first acknowledg zimmer biomet comprehens product portfolio believ collect portfolio address wide
rang musculoskelet need system group purchas organ integr deliveri network prefer vendor comprehens
product offer provid scale breadth absorb price pressur exchang share zimmer biomet broad product portfolio
address almost area musculoskelet care includ knee hip shoulder foot ankl sport medicin biolog spine trauma diagnost
elbow cmf thorac bone heal limb salvag among area provid custom varieti product
addit zimmer biomet bolster product offer acquisit may serv platform technolog provid end-to-end solut
move beyond core orthoped surgic implant product name med-tech rosa surgic robot clinic graphic range-of-mot
simul technolog respondwel tele-rehabilit platform provid post-surg physic therapi patient home other time
believ addit acquisit serv zimmer biomet well health system partner manufactur alreadi see exampl
partnership medic technolog compani neutral analyst lavin agreement lehigh valley health
network call reduct cost care multi-year period highlight zimmer biomet stand-out product
manag know need turn ship around
given zimmer biomet qualiti suppli challeng management commentari indic us zimmer biomet know
need improv qualiti stabil suppli view first step toward resolut walk zimmer biomet focu area
improv execut address near-term challeng
execut qualiti remedi management spent significantli improv qualiti relat manufactur still spend
signific amount believ zimmer biomet make progress toward qualiti remedi note qualiti remedi
relat specif issu product perform still on-go dialogu fda could delay timelin full
remedi enter earn call management hope zimmer biomet would abl resolv qualiti remedi north
warsaw campu base management commentari earn call would appear remedi take longer previous
anticip given resolut continu qualiti remedi rest fda point difficult determin
long process drag base convers management set timelin fda come back mean may
take week month even longer
suppli resolut management continu produc suffici suppli variou impact product line believ name
product provid custom assur suppli disrupt addit zimmer biomet replenish safeti
stock mani product impact earn call management complet satisfi compani
note improv help support better-than-expect result
launch new product on-go suppli challeng resolv zimmer biomet begin launch new product rep go
offens believ zimmer biomet strong product pipelin could provid suffici new product cadenc sale forc
believ import restor stabil exist product suppli custom base zimmer biomet goe offens
cultur improv zimmer acquir biomet april even year one ceo bryan hanson focus cultur
improv integr within zimmer biomet would seem logist corpor function fulli integr
legaci compani management commentari indic us may still divis legaci zimmer legaci biomet employe
addit believ employe hope return better perform moral weak may issu amongst sale forc
given previous state suppli challeng mr hanson made focu improv compani cultur believ go long way
zimmer biomet acquir med-tech juli french develop robot applic medical-surg intervent zimmer biomet paid
compani time acquisit med-tech alreadi receiv ce mark europ clearanc us rosa spine
rosa brain robot assist surgic platform commerci sale underway zimmer biomet intent system develop robot
applic joint reconstruct see momentum mako sinc time acquisit zimmer biomet make
progress rosa system recon applic applic expect full scale commerci launch beta-test
preliminari launch begin
rosa zimmer biomet offer broadli applic robot system exist applic brain spine futur applic joint
reconstruct recogn compani robot offer area spine joint reconstruct globu medic
neutral excelsiusgp system ad new indic spine long-term potenti brain trauma mazor robot mzor
rate system spine mako smith nephew navio within reconstruct said rosa may appeal custom
basi broad applic save custom need buy multipl system across specialti joint recon applic ultim compat
base medtech websit rosa current instal base unit within us today numer other ou site didnt purchas
rosa joint replac applic origin believ could open trial rosa joint reconstruct upon releas tka
applic signific differ applic hardwar joint reconstruct applic
figur zimmer biomet rosa robot system current us instal base
zimmer biomet could reduc exposur orthoped long-term
one question often ask new ceo bryan hanson given mr hanson background previous evp presid
minim invas therapi group whether zimmer biomet open expand product offer beyond musculoskelet new medic devic
market segment may higher growth exist market opportun believ near-term object compani stabil
believ management open look beyond core musculoskelet product believ investor would look favor potenti reason
price diversifi zimmer biomet revenu base away musculoskelet long compani weight averag market growth rate
current zimmer biomet total revenu expos market stabl persist price pressur name knee hip spine cmf
 dental may less expos price pressur significantli higher smith nephew
perfectli comfort potenti move adjac and/or potenti white space would allow us
diversifi growth engin keep eye weight averag market growth increas ceo bryan hanson investor
strong ebitda margin compar peer lead outsiz free cash flow
zimmer biomet maintain one better margin profil large-cap med-tech compar peer even pressur expect increas gross
margin discuss note zimmer biomet adj ebitda margin net margin expect remain higher end peer
per factset consensu zimmer biomet undergo turnaround strength margin profil help support zimmer biomet share
price margin profil lead strong free cash flow yield follow earn call note zimmer biomet increas expect free
cash flow previous driven higher net cash provid oper activ given strong free cash flow
expect expect abl make progress toward debt reduct reduc higher-than-averag leverag ratio amongst peer
pay debt like near-term primari capit alloc strategi leverag ratio come
figur ebitda margin vs net margin large-cap med-tech left consensu free cash flow yield large-cap med-tech right
ceo bryan hanson note earn call zimmer biomet like two-year turnaround definit turnaround isnt
defin specif suspect mr hanson believ like take year zimmer biomet grow market management
defin across collect busi guidanc call growth favor fx oper growth
like come given expect grow faster rate believ possibl put
return market growth like end market growth market growth timelin hold
valuat appear compel ntm price-to-earnings vs ntm price-to-earnings suspect investor may interest play turnaround
numer aspect mr hanson up-front daunt realiz take helm zimmer biomet name
qualiti remedi challeng greater anticip still numer cultur integr challeng associ legaci zimmer
legaci biomet employe resolv long-term project view limit upsid share sale momentum may
constrain suppli limit potenti mid-level leadership departur competit pressur entrench player
addit difficult know whether two-year timelin mr hanson set promise/ov deliv situat may
unforeseen challeng may unknown time believ two-year timelin may achiev zimmer biomet challeng
numer variabl remedi fda regard observ improv employe integration/moral new product
introductions/delay could push timelin
regulatori challeng could requir invest forese futur
even zimmer biomet work issu brought observ came compani receiv addit
observ midway remedi april delay stabil north warsaw facil addit
observ go anoth seri interact fda could delay product continu add cost qualiti
remedi expens management recent investor confer state conceiv think els could term addit
improv invest qualiti remedi impli onu fda provid remedi requir addit zimmer biomet
respond fda regard recent observ recent earn call management note new updat
report on-go issu answer question regard observ respons leav us concern time resolut
appear move management respons question around topic suggest littl done fda respond
may true believ fda come back numer remedi request may hamper product requir addit expens recent
commentari earn call assuag concern issu would resolv time manner management unabl commit
timelin complet
sustain gross margin pressur head
due challeng north warsaw facil focu qualiti remedi zimmer biomet abl take product initi
would off-set price headwind management expect result sustain gm pressur addit due strengthen dollar foreign
currenc translat result addit gm pressur model bottom return growth subsequ quarter
albeit modest
figur zimmer biomet gm om histor project left large-cap med-tech compar right
enter robot market inning
zimmer biomet expect total knee applic avail full commerci launch rosa system limit launch
commenc believ robot offer joint reconstruct becom paramount larg player space worri
zimmer biomet disadvantag come market behind entrench competitor smith nephew expect market
joint reconstruct robot provid opportun numer player also expect primarili smith nephew secondarili
continu grow exist custom base make challeng zimmer biomet gain meaning share note zimmer biomet
us custom base current own rosa system current form non-joint replac applic may help initi
commerci traction joint replac applic
employe moral continu challeng cultur chang usual take longer expect
corpor cultur turn-around overnight fact compani cultur chang improv employe moral slow often take year
new management improv believ one key challeng zimmer biomet management improv employe moral corpor cultur suppli
challeng left mani sale peopl account mainten mode suppli could consist expect custom new product
launch scale back believ impact top-lin result like result employe departur
compar zimmer biomet overal rate employe review site glassdoor com note averag rate star scale
rate profil declin past two year seen chart note recent rate appear hit low
begun stabil recent appoint ceo bryan hanson expect zimmer biomet continu invest higher level order
retain employe fill open posit improv overal moral expect cultur improv remain top prioriti management zimmer biomet
rate slightli ahead smith nephew depuy synth maintain steadi rate base
varieti factor includ cultur valu work/lif balanc senior manag comp benefit career opportun
pleas note differ scale graph
portfolio manag may help improv averag growth rate much
one question commonli ask management whether zimmer biomet want remain dental busi zimmer biomet offer variou
dental implant bone graft substitut instrument digit dentistri solut zimmer biomet dental busi lsd declin
straight quarter revenu base management state whether sell dental busi recent investor confer management
state activ manag product portfolio indic interest anoth strateg zimmer biomet may will sell
dont expect busi fetch much premium zimmer biomet sell would improv overal growth compani slightli
math feel could prove posit step forward zimmer term shed non-perform asset ultim littl
improv overal growth impact share may minim
leverag improv still high end peer limit opportun
zimmer biomet current net debt leverag ratio improv histor level still higher end med-tech
peer believ limit zimmer capabl near-term major zbh free cash flow servic exist debt
estim zimmer biomet back line peer leverag ratio standpoint
figur zimmer biomet leverag ratio larg cap leverag ratio net debt/ebitda
continu price pressur expect forese futur
note previous zimmer biomet exposur market consist stabl price pressur lsd risk expect larg joint orthoped
spine continu price pressur forese futur given zimmer biomet proport revenu within larg joint
orthoped spine total revenu acceler current level price pressur may impact share believ zimmer biomet abl
diversifi revenu base higher growth market risk may abat
zimmer biomet current trade ntm price-to-earnings compar median multipl zimmer biomet trade ntm price-to-earnings rel
 equip servic composit line median rel multipl indic
figur ntm price-to-earnings rel healthcar equip servic
zimmer biomet rate neutral zimmer biomet trade estim next twelve-month ep project versu comp group
forecast revenu compound-annual-growth-rate comp group forecast ep compound-annual-growth-rate also
comp group feel discount overal comp group warrant given zimmer biomet current top-lin growth expect
near-term challeng associ product qualiti remedi btig publish price target neutral rate stock
price-to-earnings rel price-to-earnings rel hcntm laboratoriesabtneutr inc baxnot dickinsonbdxnot scientificbsxbuy lifesciencesewneutr nephew adrsnnnot varneutr factset data btig estim ex-amortev/salescagrcompanytickerr ptpricemarket cap
trade analysi trade event
zimmer biomet primarili list new york stock exchang stock adv share dollar valu
adv share dollar valu
fda commun regulatori updat believ zimmer biomet updat regulatori agenc current import
determin success sway investor sentiment significantli up/down believ posit updat zimmer biomet product statu
within north warsaw facil may signific boost share convers fda come back remedi effort process
improv may delay zimmer biomet return normal product capac share may suffer
quarterli earn quarter zimmer biomet provid detail commerci progress trend compani profit believ key
metric zimmer biomet revenu growth overal segment organ revenu growth adjust gross margin adjust ebitda adjust
zimmer biomet diversifi medic technolog compani design manufactur broad rang orthoped reconstruct product zimmer
hold found justin zimmer took current form zimmer acquir biomet inc april today zimmer biomet
oper global countri employe across world
zimmer biomet long-term goal includ return subsequ grow market growth rate time investor expect modest
oper margin improv return ep growth beyond
figur zimmer biomet report structur left compani mission right
zimmer knee segment hold compani portfolio partial total knee replac alongsid adjac technolog product includ
persona person knee system nexgen complet knee solut oxford partial knee segment repres compani sale
gener sale america emea apac
hip segment compani offer hip replac revis solut key product includ m/l taper hip prosthesi taperloc hip
continuum acetabular sale segment repres compani total segment sale come primarili
america follow emea apac
compani segment compris zimmer surgic sport medicin biolog foot ankl extrem trauma product major brand
segment includ tourniquet system gel-on cross-link hyaluron comprehens shoulder segment sale repres
compani total
spine cmf segment contain compani product treat neck back pain caus spinal injuri alongsid treat bone
injuri face skull chest key product segment includ polari spinal system mobi-c cervic disc sternalock rigid sternal
fixat spine cmf sale made compani sale
zimmer dental segment manufactur reconstruct prosthet regen product dental applic compani two major dental
brand taper screw-vent implant implant dental segment repres sale compani
final segment zimmer busi made primarili compani bone cement offic base product includ palaco bone cement
spinalpak spinal fusion stimul segment gener sale zimmer
bryan hanson presid ceo mr hanson join zimmer biomet presid ceo decemb addit role zimmer
biomet mr hanson current serv board americar emerg respons global health organ previous held leadership role
medtron minim therapi group serv leadership role across busi line covidien receiv bachelor scienc
financ florida state univers complet kellogg school manag financ execut harvard execut educ
leadership program
daniel florin execut vice presid cfo mr florin appoint current execut vice presid role februari
serv cfo sinc june previous serv biomet senior vice presid cfo june prior join biomet mr florin held
leadership role bard mr florin receiv bachelor degre univers notr dame execut
coleman lannum cfa senior vice presid investor relat mr lannum serv current role sinc march previous
held senior investor relat role covidien tyco healthcar mr lannum receiv bachelor degre washington univers
 texa univers
incom etot y/i sale special oper incom incom tax expens net share net incom share gross net net oper tax expens btig research estim compani report
revenu y/i btig research estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
